Skip to main content
Premium Trial:

Request an Annual Quote

Chinese Firm Builds Genomics Facility for Translational Research with PacBio as Major Platform

Premium

NEW YORK (GenomeWeb) − The Suqian Lakeside Pangu Gene Company in Tianjin, China, has established a new genomics facility for translational medicine research projects.

The company plans to focus on molecular-based approaches for the early diagnosis of cancer and disease recurrence, and on drug efficacy evaluation.

The new facility, located in the Tianjin Dong Li Lake Technology Park, has 1,500 square meters of lab space and will be using Pacific Biosciences' PacBio RS II as its major sequencing platform, the two firms said this week. Earlier this year, SLPC purchased four PacBio RS II systems, which were recently installed.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.